| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
a Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
b Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
c Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio
Accepted for publication July 20, 2007.
* Address correspondence to Dr Smedira, Kaufman Center for Heart Failure, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, 9500 Euclid Avenue/F24, Cleveland, OH 44195 (Email: smidern{at}ccf.org).
Background: Septal myectomy is the gold-standard therapy for hypertrophic obstructive cardiomyopathy (HOCM). However, it is being challenged by a less-invasive alternative: alcohol septal ablation. This study examined the clinical effectiveness and risks of isolated septal myectomy for HOCM.
Methods: From January 1994 to January 2005, 323 patients underwent isolated septal myectomy (mean age 50 ± 14 years, 53% male). Preoperative septal thickness was 2.3 ± 0.46 cm and peak left ventricular outflow tract (LVOT) gradient 68 ± 43 mm Hg. Effectiveness of myectomy was assessed by echocardiography, sudden death, and functional limitation, early risks by intraoperative and postoperative complications, and late risks by follow-up for HOMC-related reoperation, heart block, and all-cause mortality (mean 3.6 ± 2.8 years, 1,152 patient-years, 10% followed 
8 years).
Results: Myectomy was effective, resulting in sustained decrease in septal thickness and LVOT gradient, absence of sudden death, and improved functional status. Early in-hospital morbidity was low, with no hospital deaths; two iatrogenic ventricular septal defects were repaired uneventfully, and 22 pacemakers were required for heart block. In the intermediate term, 10 patients required HOCM-related reoperations (4 redo myectomies, 6 mitral valve procedures), with 92% freedom from reoperation at eight years. Seventy-nine percent were free of pacemakers by 8 years, and survival was 90%, equivalent to that of the general population.
Conclusions: Isolated septal myectomy is effective in eliminating LVOT obstruction and sudden death and in improving functional status, with low operative morbidity and mortality. Few reoperations are required late and outcomes are excellent. It should be considered the treatment of choice for HOCM.
Related Article
Ann. Thorac. Surg. 2008 85: 133-134.
This article has been cited by other articles:
|
|
 |
|
  B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 13, 2011; 58(25): 2703 - 2738. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 13, 2011; 58(25): e212 - e260. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 13, 2011; 124(24): e783 - e831. [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 13, 2011; 124(24): 2761 - 2796. [Full Text] [PDF]
|
|
|
|
|
|
N. Sreeram, M. Emmel, and J. V. de Giovanni Percutaneous Radiofrequency Septal Reduction for Hypertrophic Obstructive Cardiomyopathy in Children J. Am. Coll. Cardiol., December 6, 2011; 58(24): 2501 - 2510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members:*, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Thorac. Cardiovasc. Surg., December 1, 2011; 142(6): 1303 - 1338. [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members:*, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Thorac. Cardiovasc. Surg., December 1, 2011; 142(6): e153 - e203. [Full Text] [PDF]
|
|
|
|
|
|
S. F. Nagueh, B. M. Groves, L. Schwartz, K. M. Smith, A. Wang, R. G. Bach, C. Nielsen, F. Leya, J. M. Buergler, S. K. Rowe, et al. Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy: A Multicenter North American Registry J. Am. Coll. Cardiol., November 22, 2011; 58(22): 2322 - 2328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Elliott The Role of Alcohol Septal Ablation in the Treatment of Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., November 22, 2011; 58(22): 2329 - 2331. [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Jensen, V. M. Almaas, L. Jacobsson, P. R. Hansen, O. Havndrup, S. Aakhus, B. Svane, T. F. Hansen, L. Kober, K. Endresen, et al. Long-Term Outcome of Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: A Scandinavian Multicenter Study Circ Cardiovasc Interv, June 1, 2011; 4(3): 256 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Maron, M. Yacoub, and J. A. Dearani Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients Eur. Heart J., May 1, 2011; 32(9): 1055 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Fifer and U. Sigwart Hypertrophic obstructive cardiomyopathy: alcohol septal ablation Eur. Heart J., May 1, 2011; 32(9): 1059 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Brown, H. V. Schaff, J. A. Dearani, Z. Li, R. A. Nishimura, and S. R. Ommen Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomyopathy J. Thorac. Cardiovasc. Surg., February 1, 2011; 141(2): 439 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-H. Kim, M. D. Handschumacher, R. A. Levine, Y.-S. Choi, Y. J. Kim, S.-C. Yun, J.-M. Song, D.-H. Kang, and J.-K. Song In Vivo Measurement of Mitral Leaflet Surface Area and Subvalvular Geometry in Patients With Asymmetrical Septal Hypertrophy: Insights Into the Mechanism of Outflow Tract Obstruction Circulation, September 28, 2010; 122(13): 1298 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Kwon, N. G. Smedira, M. Thamilarasan, B. W. Lytle, H. Lever, and M. Y. Desai Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation J. Thorac. Cardiovasc. Surg., August 1, 2010; 140(2): 317 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vegas and M. Meineri Core Review: Three-Dimensional Transesophageal Echocardiography Is a Major Advance for Intraoperative Clinical Management of Patients Undergoing Cardiac Surgery: A Core Review Anesth. Analg., June 1, 2010; 110(6): 1548 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Nishimura and S. R. Ommen Septal Reduction Therapy for Obstructive Hypertrophic Cardiomyopathy and Sudden Death: What Statistics Cannot Tell You Circ Cardiovasc Interv, April 1, 2010; 3(2): 91 - 93. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Leonardi, E. P. Kransdorf, D. L. Simel, and A. Wang Meta-Analyses of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy: Comparative Rates of Overall Mortality and Sudden Cardiac Death After Treatment Circ Cardiovasc Interv, April 1, 2010; 3(2): 97 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Agarwal, E. M. Tuzcu, M. Y. Desai, N. Smedira, H. M. Lever, B. W. Lytle, and S. R. Kapadia Updated Meta-Analysis of Septal Alcohol Ablation Versus Myectomy for Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., February 23, 2010; 55(8): 823 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kayalar, H. V. Schaff, R. C. Daly, J. A. Dearani, and S. J. Park Concomitant Septal Myectomy at the Time of Aortic Valve Replacement for Severe Aortic Stenosis Ann. Thorac. Surg., February 1, 2010; 89(2): 459 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D H Kwon, N G Smedira, Z B Popovic, B W Lytle, R M Setser, M Thamilarasan, P Schoenhagen, S D Flamm, H M Lever, and M Y Desai Steep left ventricle to aortic root angle and hypertrophic obstructive cardiomyopathy: study of a novel association using three-dimensional multimodality imaging Heart, November 1, 2009; 95(21): 1784 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K.N. Wan, J. A. Dearani, T. M. Sundt III, S. R. Ommen, and H. V. Schaff What Is the Best Surgical Treatment for Obstructive Hypertrophic Cardiomyopathy and Degenerative Mitral Regurgitation? Ann. Thorac. Surg., September 1, 2009; 88(3): 727 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Kwon, N. G. Smedira, E. R. Rodriguez, C. Tan, R. Setser, M. Thamilarasan, B. W. Lytle, H. M. Lever, and M. Y. Desai Cardiac Magnetic Resonance Detection of Myocardial Scarring in Hypertrophic Cardiomyopathy: Correlation With Histopathology and Prevalence of Ventricular Tachycardia J. Am. Coll. Cardiol., July 14, 2009; 54(3): 242 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S R Ommen, P M Shah, and A J Tajik Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future Heart, October 1, 2008; 94(10): 1276 - 1281. [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Kwon, S. R. Kapadia, E. M. Tuzcu, C. M. Halley, E. Z. Gorodeski, R. J. Curtin, M. Thamilarasan, N. G. Smedira, B. W. Lytle, H. M. Lever, et al. Long-Term Outcomes in High-Risk Symptomatic Patients With Hypertrophic Cardiomyopathy Undergoing Alcohol Septal Ablation J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 432 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Sigwart Catheter Treatment for Hypertrophic Obstructive Cardiomyopathy: For Seniors Only? Circulation, July 8, 2008; 118(2): 107 - 108. [Full Text] [PDF]
|
|
|
|
|
|
J. Dearani Invited commentary Ann. Thorac. Surg., January 1, 2008; 85(1): 133 - 134. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
